Cargando…

A bacteria-based system expressing anti-TNF-α nanobody for enhanced cancer immunotherapy

Detalles Bibliográficos
Autores principales:	Liu, Lina, Liu, Xing, Xin, Wenjie, Zhou, Lulu, Huang, Baolian, Han, Chao, Cao, Zhiting, Hua, Zichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113364/ https://www.ncbi.nlm.nih.gov/pubmed/37072393 http://dx.doi.org/10.1038/s41392-023-01364-0

Ejemplares similares

Neutrophil‐Mediated Tumor‐Targeting Delivery System of Oncolytic Bacteria Combined with ICB for Melanoma Lung Metastasis Therapy
por: Liu, Lina, et al.
Publicado: (2023)

Properties of Fluorescent Far-Red Anti-TNF Nanobodies
por: Gorshkova, Ekaterina N., et al.
Publicado: (2018)

Ozoralizumab, a Humanized Anti-TNFα NANOBODY(®) Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG
por: Ishiwatari-Ogata, Chihiro, et al.
Publicado: (2022)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review)
por: Yu, Sheng, et al.
Publicado: (2021)

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY(®) compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

Nanobody-based CAR-T cells for cancer immunotherapy
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)

Editorial: Nanobody-based cancer immunotherapy and immunoimaging
por: Jafari, Mahdie, et al.
Publicado: (2023)

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
por: Tezera, Liku B, et al.
Publicado: (2020)

Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY(®) compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation
por: Kyuuma, Masanao, et al.
Publicado: (2023)

Nanobodies in cell-mediated immunotherapy: On the road to fight cancer
por: Maali, Amirhosein, et al.
Publicado: (2023)

Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ
por: Butler, David C., et al.
Publicado: (2016)

Assessment of Anti-TNF-α Activities in Keratinocytes Expressing Inducible TNF- α: A Novel Tool for Anti-TNF-α Drug Screening
por: Udommethaporn, Sutthirat, et al.
Publicado: (2016)

TNF-α/anti-TNF-α drugs and its effect on pregnancy outcomes
por: Dai, Fang-fang, et al.
Publicado: (2022)

Anti-TNF, a magic bullet in cancer immunotherapy?
por: Montfort, Anne, et al.
Publicado: (2019)

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer
por: Chanier, Timothée, et al.
Publicado: (2019)

The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding
por: Romanowska-Próchnicka, Katarzyna, et al.
Publicado: (2021)

Intratumoural production of TNFα by bacteria mediates cancer therapy
por: Murphy, Carola, et al.
Publicado: (2017)

Transmembrane TNF-α: structure, function and interaction with anti-TNF agents
por: Horiuchi, Takahiko, et al.
Publicado: (2010)

Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report
por: Schoffelen, Teske, et al.
Publicado: (2014)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Interaction standards for biophysics: anti-lysozyme nanobodies
por: Birchenough, Holly L., et al.
Publicado: (2021)

Anti-TNF-α Therapy for Ankylosing Spondylitis
por: Son, Jung-Hwan, et al.
Publicado: (2010)

Anti-TNF-α therapy in membranous glomerulonephritis
por: Santoro, Domenico, et al.
Publicado: (2012)

Identification and characterization of blocking nanobodies against human CD70: Identification and characterization of blocking nanobodies
por: Zhang, Xin, et al.
Publicado: (2022)

Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhimurium VNP20009 in anti-PD1 therapy against melanoma
por: Wu, Leyang, et al.
Publicado: (2022)

Nanobody-Nanoluciferase Fusion Protein-Enabled Immunoassay for Ochratoxin A in Coffee with Enhanced Specificity and Sensitivity
por: Bao, Kunlu, et al.
Publicado: (2022)

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
por: Yang, Xiao-mei, et al.
Publicado: (2023)

Recombinant expression of nanobodies and nanobody-derived immunoreagents
por: de Marco, Ario
Publicado: (2020)

α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice
por: Butler, Yemima R., et al.
Publicado: (2022)

The intensity of joint pain in relation to changes in serum TNFα during therapy with anti-TNFα inhibitors
por: Sikorska, Dorota, et al.
Publicado: (2019)

Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies
por: Caljon, Guy, et al.
Publicado: (2012)

Resolving bundled microtubules using anti-tubulin nanobodies
por: Mikhaylova, Marina, et al.
Publicado: (2015)

Anti-TNF-α Therapies in Systemic Lupus Erythematosus
por: Zhu, Lang-Jing, et al.
Publicado: (2010)

Autoimmune Hepatitis Triggered by Anti-TNF-α Therapy
por: Nakayama, Satoshi
Publicado: (2013)

Anti-TNF-α and hydralazine drug-induced lupus
por: Quaresma, Maria Victória, et al.
Publicado: (2015)

Effects of anti-TNF-α in experimental diversion colitis
por: Buanaim, Ronaldo Parisi, et al.
Publicado: (2019)

Anti-TNF-α Compounds as a Treatment for Depression
por: Uzzan, Sarit, et al.
Publicado: (2021)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

Preparation of a Nanobody Specific to Dectin 1 and Its Anti-inflammatory Effects on Fungal Keratitis
por: Liu, Xing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_elqpub4dsg65dnujph7ok6fdal